Wnt-Frizzled signaling interface (Wnt-FZD interface)

The Wnt-Frizzled signaling interface is the primary extracellular site of activation for the Wnt signaling pathway, involving the binding of secreted Wnt glycoproteins to the cysteine-rich domain (CRD) of Frizzled (FZD) receptors and their co-receptors, such as LRP5/6 (NIH, 2024). This interaction triggers a cascade of intracellular events, most notably the stabilization and nuclear translocation of β-catenin, which regulates the transcription of genes involved in cell proliferation, differentiation, and fate determination (NIH, 2024; MDPI, 2023). Dysregulation of this interface, often through ligand overexpression or receptor upregulation, is a hallmark of various malignancies, including colorectal, breast, and pancreatic cancers, as well as fibrotic and bone diseases (NIH, 2024; JKSUS, 2018). Therapeutic strategies targeting this interface include monoclonal antibodies that neutralize FZD receptors (e.g., vantictumab), decoy receptors that sequester Wnt ligands (e.g., ipafricept), and inhibitors of Wnt secretion (e.g., porcupine inhibitors) (NIH, 2024; AACR, 2015). However, drug development faces significant challenges due to the essential role of Wnt signaling in adult tissue homeostasis, particularly in the bone and gastrointestinal tract (NIH, 2024). This leads to potential toxicities such as bone loss (osteoporosis) and mucosal damage (diarrhea), which have limited the clinical progression of several candidates (NIH, 2024; ACS, 2021). Biomarkers such as RNF43/ZNRF3 mutations and RSPO fusions are increasingly used to identify patients most likely to benefit from these upstream Wnt inhibitors (AACR, 2015; Gut, 2020).

Other names

Wnt-Frizzled receptor complexWnt-FZD interactionExtracellular Wnt-Frizzled signaling interfaceWnt-Frizzled-LRP5/6 complexWnt ligands / extracellular Wnt–Frizzled signaling interface

Competitive inhibition of Wnt-Frizzled binding, sequestration of Wnt ligands by decoy receptors, neutralization of Frizzled receptors by monoclonal antibodies, and inhibition of Wnt ligand secretion via Porcupine inhibition (NIH, 2024; AACR, 2015).